奥扎格雷钠联合纤溶酶治疗急性进展型脑梗死疗效分析

目的探讨奥扎格雷钠联合纤溶酶治疗急性进展型脑梗死的临床疗效。方法选择2011年5月～2012年5月本院收治的58例急性进展型脑梗死患者,随机分为观察组和对照组,观察组采用奥扎格雷钠联合纤溶酶进行治疗;对照组单独采用奥扎格雷钠进行治疗,对两组患者治疗前后的神经功能缺损评分,临床治疗效果以及实验室指标进行比较。结果观察组治疗后神经功能缺损评分明显低于对照组,而总有效率明显高于对照组,差异有统计学意义（P〈0.05）;实验室指标显示,观察组纤维蛋白原明显降低,与对照组比较,差异有统计学意义（P〈0.05）。结论奥扎格雷钠联合纤溶酶治疗急性进展型脑梗死效果好,能够显著改善急性进展型脑梗死患者的神经功能,具有良好的安全性,值得临床推广使用。

Efficacy of acute progressive cerebral infarction treated by Ozagrel Sodium and Plasminogen

Objective To study the efficacy of acute progressive cerebral infarction treated by Ozagrel Sodium and Plasminogen. Methods Fifty-eight cases of acute progressive cerebral infarction patients who were from May 2011 to May 2012 in our hospital, were randomly divided into observation group and control group, the observation group was treated by Ozagrel Sodium and Plasminogen, control group was treated only by Ozagrel Sodium, neurological deficit score, clinical outcomes and laboratory indicators of two groups were compared before and after treatment. Results After treatment, the neurological function of the observation group was significantly lower than the control group, while the total efficiency was significantly higher than the contol group, difference had statistical significance (P < 0.05), laboratory parameters the fibrinogen of observer group was significantly lower than the control group, difference had statistical significance (P < 0.05). Conclusion The effects that treated acute progressive cerebral infarction by Ozagrel Sodium and Plasminogen, and both of them can significantly improve the acute progressive cerebral infarction in patients with nerve function, with good security, is worthy of clinical use.